The goal of our study was to evaluate differences in NT-proBNP levels and outcomes among patients with HFrEF with and without AF who were enrolled in the GUIDE-IT trial, an RCT designed to evaluate the efficacy of an NT-proBNP–guided HF treatment strategy. This evidence concerns the gene NPPB and atrial fibrillation.